Amir Heshmatpour Purchases 35,000 Shares of Neonc Technologies (NASDAQ:NTHI) Stock

Posted by Francis Steltz on Sep 17th, 2026

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI – Get Free Report) CEO Amir Heshmatpour bought 35,000 shares of Neonc Technologies stock in a transaction on Tuesday, September 15th. The shares were bought at an average price of $3.30 per share, for a total transaction of $115,500.00. Following the acquisition, the chief executive officer owned 3,183,000 shares of the company’s stock, valued at approximately $10,503,900. The trade was a 1.11% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Neonc Technologies Stock Down 9.7%

Shares of NTHI stock opened at $2.99 on Thursday. The stock has a 50-day moving average of $4.01 and a 200-day moving average of $5.22. Neonc Technologies Holdings, Inc. has a one year low of $2.95 and a one year high of $12.99.

Neonc Technologies (NASDAQ:NTHI – Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.46).

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Westmount Partners LLC raised its holdings in shares of Neonc Technologies by 355.2% during the second quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock worth $893,000 after acquiring an additional 153,858 shares during the period. BlackRock Inc. acquired a new position in Neonc Technologies in the 2nd quarter worth $815,000. Bank of America Corp DE bought a new position in Neonc Technologies during the 2nd quarter worth about $1,017,000. Finally, Global Retirement Partners LLC bought a new position in Neonc Technologies during the 2nd quarter worth about $126,000.

Analysts Set New Price Targets

NTHI has been the subject of a number of recent analyst reports. Weiss Ratings upgraded shares of Neonc Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 31st. Wall Street Zen cut Neonc Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, BTIG Research restated a “buy” rating and issued a $15.00 price target on shares of Neonc Technologies in a report on Tuesday, September 8th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Neonc Technologies presently has an average rating of “Hold” and an average target price of $16.00.

Get Our Latest Report on NTHI

Neonc Technologies News Summary

Here are the key news stories impacting Neonc Technologies this week:

Positive Sentiment: Executives, including CEOs Amir F. Heshmatpour and Thomas C. Chen and CFO Keithly Garnett, bought shares in multiple transactions. Heshmatpour purchased a combined 87,000 shares across recent trades, while Chen bought 10,798 shares. The purchases may signal management confidence that NTHI is undervalued. NeOnc executive stock purchase announcement
Positive Sentiment: Positive Phase 2a data for NEO100 has shifted investor focus toward the program’s next regulatory milestone and the possibility of FDA engagement. Further clinical or regulatory progress could provide a catalyst for the shares. NEO100 data and FDA article
Positive Sentiment: NeOnc’s targeted-delivery platform and additional CNS cancer candidates, including preclinical NEO212, provide potential long-term value if the company can advance its pipeline successfully. NeOnc platform and pipeline article
Neutral Sentiment: Analyst views are mixed: three analysts rate NTHI Buy, one rates it Hold and one rates it Sell. The reported consensus is Hold, despite price targets well above the current trading range, reflecting the uncertainty of an early-stage biotechnology company.
Negative Sentiment: NeOnc’s latest quarterly loss of $0.58 per share was substantially worse than the expected $0.12 loss, raising concerns about cash burn and the funding needed to reach commercialization.
Negative Sentiment: A recent roughly $15 million financing may support NEO100 development, but potential equity issuance can dilute existing shareholders. The shares have also declined sharply, remain below their 50-day and 200-day moving averages, and are near their 12-month low.

Neonc Technologies Company Profile

(Get Free Report)

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.